BioNTech SE Stock Sao Paulo

Equities

B1NT34

BRB1NTBDR005

Biotechnology & Medical Research

Market Closed - Sao Paulo 15:49:52 2024-05-31 EDT 5-day change 1st Jan Change
33.03 BRL +10.10% Intraday chart for BioNTech SE +5.87% +3.87%

Financials

Sales 2024 * 2.75B 2.98B 15.65B 4.07B Sales 2025 * 2.75B 2.99B 15.67B 4.07B Capitalization 22.39B 24.29B 127B 33.11B
Net income 2024 * -435M -472M -2.47B -643M Net income 2025 * -572M -621M -3.25B -846M EV / Sales 2024 * 3.38 x
Net cash position 2024 * 13.08B 14.19B 74.41B 19.34B Net cash position 2025 * 12.47B 13.53B 70.94B 18.44B EV / Sales 2025 * 3.6 x
P/E ratio 2024 *
-51.4 x
P/E ratio 2025 *
-41.5 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+10.10%
1 week+5.87%
1 month+14.33%
3 months+19.16%
6 months+9.55%
Current year+3.87%
More quotes
1 week
29.60
Extreme 29.6
33.96
1 month
28.56
Extreme 28.56
33.96
Current year
26.81
Extreme 26.81
35.26
1 year
26.81
Extreme 26.81
38.56
3 years
26.81
Extreme 26.81
66.08
5 years
26.81
Extreme 26.81
66.08
10 years
26.81
Extreme 26.81
66.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 70 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-05-31 33.03 +10.10% 4,745
24-05-29 30 -0.70% 17
24-05-28 30.21 -2.71% 1,551
24-05-27 31.05 -0.48% 1,931
24-05-24 31.2 -2.32% 474

Delayed Quote Sao Paulo, May 31, 2024 at 03:49 pm

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
92.76 EUR
Average target price
103.1 EUR
Spread / Average Target
+11.16%
Consensus